The US Biomedical Advanced Research and Development Authority (BARDA) is already developing a vaccine for monkeypox. Although the disease may seem novel, the first reported outbreak in monkeys occurred in 1958, and the first human infection was reported in the 1970s in the Democratic Republic of the Congo (DRC). According to the Centers for Diseases and Prevention (CDC), the virus is transmitted to humans through direct animal-to-human or human-to-human contact. Before they change the transmission guidelines, I will report what they stated on their website:
“Transmission of monkeypox virus occurs when a person comes into contact with the virus from an animal, human, or materials contaminated with the virus. The virus enters the body through broken skin (even if not visible), respiratory tract, or the mucous membranes (eyes, nose, or mouth). Animal-to-human transmission may occur by bite or scratch, bush meat preparation, direct contact with body fluids or lesion material, or indirect contact with lesion material, such as through contaminated bedding. Human-to-human transmission is thought to occur primarily through large respiratory droplets. Respiratory droplets generally cannot travel more than a few feet, so prolonged face-to-face contact is required. Other human-to-human methods of transmission include direct contact with body fluids or lesion material, and indirect contact with lesion material, such as through contaminated clothing or linens.”
The disease can reportedly occur through sexual encounters as well. This is NOT an airborne virus – masks and lockdowns would be useless. Cases of the virus are appearing throughout the world, but again, this virus was never limited to one continent. In 2003, 47 cases of monkeypox were reported in the US after pet prairie dogs became infected after being housed with small animals imported from Ghana.
BARDA plans to release JYNNEOS, a smallpox vaccine, to treat monkeypox cases by 2023. The company has already produced almost 13 million freeze-dried doses of the vaccine that are expected to be manufactured in 2024 and 2025.
President and CEO of Bavarian Nordic Paul Chaplin said, “We are pleased to announce the exercise of the first options under our contract with the US government to deliver a freeze-dried version of the smallpox vaccine with an improved shelf-life, which will be manufactured at our new fill and finish facility. This marks a significant milestone in our long-standing partnership with the US government to ensure the availability of life-saving vaccines for the entire population.”
The European Medicines Agency approved the medication to treat monkeypox in 2013, and the FDA quietly approved its usage in 2019. Since this seems to be a rare illness, why are they planning to manufacture millions of doses to save “the entire population?” The media has only just begun reporting cases of the virus, and it would not be surprising if they pushed yet another unnecessary vaccine on the global population for profit and control.